智通财经APP获悉，科济药业-B(02171)涨超7%，截至发稿，涨7.49%，报16.64港元，成交额2540.24万港元。
消息面上，科济药业此前宣布，CT071（一种靶向GPRC5D的自体CAR-T细胞产品）用于治疗新诊断的多发性骨髓瘤（NDMM）的研究者发起的临床试验（NCT06407947）的研究结果摘要已被2025年欧洲血液学协会（EHA）年会接受，将在壁报展示环节进行发布。摘要和进一步信息将于欧洲中部时间2025年5月14日15:30后公布。
此外，公司宣布，舒瑞基奥仑赛注射液（产品编号：CT041，一款靶向Claudin18.2蛋白的自体CAR-T细胞治疗候选产品）在中国开展的针对晚期胃癌/食管胃结合部腺癌的确证性II期临床试验（CT041-ST-01, NCT04581473）的研究结果摘要已被2025年美国临床肿瘤学会（ASCO）年会接受进行口头报告。摘要和进一步信息将于美国东部时间2025年5月22日后公布。浙商证券此前指，按照公司年报披露预计2025H1提交晚期治疗GC/GEJ 适应症NDA，该行认为有望成为首款获批商业化的实体瘤CAR-T 药物。考虑到实体瘤患者较大的基数，看好CT041 商业化前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.